[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Policlinico Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":116},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,69,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100581261","tracheal-cuff-pressure-evaluation-study-100581261",false,"NCT06848010","TRacheal Cuff PRessure Evaluation Study","TRAC-PRES","Inclusion Criteria:\n\n* Required invasive mechanical ventilation expected to last for more than 24h\n* Signed informed consent\n\nExclusion Criteria:\n\n* Intubated from more than 6 hours at the time of screening\n* Pregnancy\n* Previous surgery involving the airways","ALL","18 Years",{"count":19,"type":20},54,"ESTIMATED","INTERVENTIONAL",[23],"NA","Randomized clinical trial in mechanically ventilate critically ill patients. The study will evaluated the efficacy of a continous endotracheal tube (ETT) cuff pressure controller (TRACH FLUSH group) compared to manual monitoring and inflation (STANDARD group).\n\nPatients intubated, from at least 24 hours and with a predicted duration of invasive mechanical ventilation longer than 72 hours, will be randomized to the use of TRACH FLUSH versus nurse operated analogic cuff pressure controller q8.\n\nHypotesis of the study is the superiority of the continuous cuff pressure controller in maintaining cuff pressure within the target value, thus decreasing the incidence of microaspiration events.\n\nAim of the study are 1) to compare the incidence of cuff pressure value detection outside the target range between the TRACH FLUSH and the STANDARD group, and 2) to compare the incidence of sputum samples positive for (amylase and\u002For pepsin), a surrogate for tracheal micro-aspiration event.",[26,27],"Pneumonia, Ventilator-Associated","Mechanical Ventilation",[29,30],"pressure cuff control","mechanical ventilation","NOT_YET_RECRUITING","2026-01-26",{"date":34,"type":35},"2026-01-28","ACTUAL",{"date":37,"type":20},"2026-02-15",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Policlinico Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100614516","the-hering-breuer-reflex-in-bilateral-lung-transplant-patients-100614516","NCT07280611","The Hering-Breuer Reflex in Bilateral Lung Transplant Patients","HB-DLTX","Inclusion Criteria:\n\n* Age \\>18 years;\n* Both sexes;\n* For group 1: patients admitted to the Intensive Care Unit after undergoing bilateral lung transplantation, during respiratory weaning;\n* For group 2: patients admitted to the Intensive Care Unit for support or monitoring after non-thoracic surgery, who will arrive intubated.\n\nExclusion Criteria:\n\nFor group 1, patients meeting at least one of the following criteria will be excluded:\n\n* Re-transplantation or single-lung transplantation;\n* Urgent lung transplantation;\n* Post-transplant respiratory system compliance \\\u003C 30 mL\u002FcmH₂O;\n* Hemodynamic instability (defined as the presence of one or more of the following: plasma lactate \\> 4 mmol\u002FL, need for vasoactive support with norepinephrine and\u002For epinephrine at a dose \\> 0.05 mcg\u002Fkg\u002Fmin, systolic arterial pressure \\\u003C 80 mmHg);\n* Increased risk of bleeding related to the placement of a nasogastric tube due to coagulopathy or severe thrombocytopenia (INR \\> 2 and platelets \\\u003C 70,000);\n* Pregnancy\n\nFor group 2, patients presenting with one or more of the following criteria will be excluded:\n\n* Postoperative respiratory system compliance \\\u003C 30 mL\u002FcmH₂O;\n* Hemodynamic instability (defined as the presence of one or more of the following: plasma lactate \\> 4 mmol\u002FL, need for vasoactive support with norepinephrine and\u002For epinephrine at a dose \\> 0.05 mcg\u002Fkg\u002Fmin, systolic arterial pressure \\\u003C 80 mmHg);\n* Contraindications to nasogastric tube placement (gastroesophageal surgery within the last 3 months, gastroesophageal bleeding in the previous 30 days, esophageal varices, facial trauma);\n* Increased risk of bleeding related to the placement of a nasogastric tube due to coagulopathy or severe thrombocytopenia (INR \\> 2 and platelets \\\u003C 70,000);\n* History of lung transplantation or major thoracic surgery;\n* Pregnancy.",{"count":52,"type":20},22,[23],"The goal of this clinical trial (non-pharmacologic, single-center) is to determine whether the Hering-Breuer inflation reflex is preserved-and how it is modulated by end-expiratory pressure-in adult intensive-care patients who have undergone bilateral lung transplantation.\n\nThe study will enroll men and women ≥ 18 years admitted to the ICU during the early weaning phase and will include a comparison group of intubated ICU patients after major non-thoracic surgery.\n\nThe main questions it aims to answer are:\n\n* Is the Hering-Breuer reflex (measured as the ratio THBR\u002FTSPONT) absent or attenuated in double-lung-transplant recipients?\n* Does changing the level of positive end-expiratory pressure (PEEP 8 vs 12 cmH₂O) influence the reflex?\n\nComparison group: Researchers will compare the transplant arm (post-bilateral lung transplantation) with the control arm (post-operative, non-thoracic surgery patients) to see whether loss or blunting of the reflex-and its response to PEEP-differs between the two cohorts.\n\nParticipants will:\n\n* Have a nasogastric catheter with embedded electrodes positioned to record the electrical activity of the diaphragm (EAdi).\n* Be ventilated in pressure-support mode at two preset PEEP levels (8 cmH₂O and 12 cmH₂O) during the weaning phase.\n* Receive one standardized high-volume insufflation at \\~30 cmH₂O in each PEEP condition to elicit the reflex, while EAdi, airway pressures, inspiratory\u002Fexpiratory times, and tidal volumes are recorded for 10 minutes per level.",[56],"Hering-Breuer Reflex",[58,59],"Hering-Breuer reflex","Bilateral Lung Transplant","RECRUITING","2025-12-01",{"date":63,"type":35},"2025-12-12",{"date":65,"type":35},"2025-10-07",{"date":67,"type":20},"2026-06",{"name":41,"class":42},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":43},"100560937","antimicrobial-therapeutic-drug-monitoring-during-lung-transplant-perioperative-phase-100560937","NCT06583642","Antimicrobial Therapeutic Drug Monitoring During Lung Transplant Perioperative Phase","Inclusion Criteria:\n\n* Recipient of LUTX\n* Age \\> 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Already undergone LUTX\n* Documented respiratory colonization in the 12 months preceding LUTX\n* Undergoing any antimicrobial therapy preceding LUTX\n* Documented post-LUTX endobronchial plasma leak requiring high levels of PEEP \\> 15 cmH2O.",{"count":76,"type":20},20,"OBSERVATIONAL","Background: Post-LUTX pneumonia represents a leading cause of death along the first month after LUTX. Donor-derived transmission of pathogenic species occurs up to 25% of recipients receiving a graft with a positive BAL culture, despite in-vitro adequate antimicrobial prophylaxis.\n\nHypothesis: LUTX recipients are either exposed to suboptimal antimicrobial doses or antimicrobial penetration into the lug parenchyma is altered either due to surgery (absence of bronchial anastomoses) or to the hyperinflammatory state.\n\nMethods: LUTX recipients admitted to the intensive care unit at the Fondazione IRCCS Ca' Granda Policlinico Hospital. According to the institutional perioperative prophylaxis protocol and the donor\u002Frecipient ecology the most frequent antimicrobial molecules administered will be: cefepime, vancomycin, and meropenem. Antimicrobial pharmacokinetics will be investigated at three timepoints. Plasma levels of the ongoing antimicrobial molecule will be assessed at ICU admission, on postoperative day 1 and on postoperative day 3. Bronchoalveolar lavage (BAL) samples for the measurement of BAL antimicrobial levels will be collected during the BAL performed for clinical indication on postoperative day 1 and on postoperative day 3.\n\nAbsolute plasma and BAL antimicrobial levels will be assessed. The ratio of BAL to plasma dosage of antimicrobial will be assessed to evaluate antimicrobial penetration within the target tissue. Correlation between both plasma and BAL antimicrobial dosage and recipients' postoperative fluid balance, body weight, vasopressor requirement, renal function will be performed.",[80,81,82],"Lung Transplant Infection","Pneumonia, Bacterial","Antibiotic Resistant Strain","2025-05-19",{"date":85,"type":35},"2025-05-22",{"date":87,"type":20},"2025-07-01",{"date":89,"type":20},"2027-03-01",{"name":41,"class":42},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100539311","renal-doppler-to-predict-acute-kidney-injury-aki-in-ards-patients-red-aki-study-100539311","NCT06302192","Renal Doppler to Predict Acute Kidney Injury (AKI) in ARDS Patients. (RED-AKI Study)","RED-AKI: Renal Doppler in Acute Kidney Injury. Capability of Intrarenal Venous Flow Doppler (IRVF) to Predict Acute Kidney Injury (AKI) in Critically Ill Patients With Acute Respiratory Distress Syndrome (ARDS)","RED-AKI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Critically ill patients admitted to intensive care unit with a diagnosis of ARDS according to Berlino criteria\n* Beginning of IMV less than 48 hours or Clinical decision to begin IMV.\n* Life expectancy \\> 24 hours\n* Informed consent signed\n\nExclusion Criteria:\n\nNo patient will be excluded from the study because of gender, race, ethnicity, or sexual preference.\n\n* AKI prior to the onset of ARDS\n* Chronic respiratory failure due to chronic respiratory diseases\n* Chronic renal disease (CKD stage ≥ 2) and any ureteral obstruction. Definition of CKD patient is according to the latest guideline KDIGO\n* Chronic Heart Failure\n* Chronic liver disease\n* Major trauma in the past 3 months\n* Major surgery in the past 3 months\n* Smoking and Alcohol drinking\n* BMI ≥ 35\n* Patients needing of VV-ECMO and VA-ECMO\n* Beginning of positive pressure ventilation more than 48 hours (invasive or no invasive)\n* Life expectancy \\\u003C24 hours\n* Cardio Circulatory Arrest\n* Neoplasm in chemotherapy\u002Fradiotherapy\n* Do Not Resuscitate or Comfort Measures\n* Pregnancy at ICU admission\n* Refused Informed Consent by the patient or surrogate decision-maker","80 Years",{"count":101,"type":20},164,"This is a multicenter international observational prospective cohort study. The main questions it aims to answer are:\n\n* PRIMARY AIM: To describe the capability of IRVF demodulation at diagnosis of ARDS to predict development of AKI within 7 days from the ARDS onset\n* SECONDARY AIMS: A)Describe the capability of IRVF demodulation or pattern of IRVF (continuous, pulsatility, biphasic, monophasic) to predict development of AKI within 14 days from the ARDS onset. B) To describe the RD parameters and VexUS in the AKI and no AKI patients over time. C) Describe the impact of invasive mechanical ventilation (IMV) on the intrarenal venous congestion and VexUS., D) Evaluation of effect of CRRT on IRVF pattern, VexUS and parameters. E) Describe the feasibility of renal doppler to assess IRVF in critically ill respiratory patients. F) Evaluate the incidence of AKD and CKD Participants will Adult patients with diagnosis of ARDS admitted to intensive care unit and undergoing invasive mechanical ventilation",[104,105],"Acute Kidney Injury","ARDS, Human",[107],"Renal Doppler","2024-03-04",{"date":110,"type":35},"2024-03-08",{"date":112,"type":20},"2024-04-01",{"date":114,"type":20},"2026-06-30",{"name":41,"class":42},""]